Recordati buys rights to rare immune disorder drug from Sanofi for $825 million
(Reuters) -Italian pharma group Recordati said on Friday it would buy from Sanofi the global rights to a drug used to treat ...
Morningstar3d
Sanofi SA ADR SNY
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
pharmaphorum4d
Sanofi will exit consumer health and boost R&D investment
Sanofi is following in the footsteps of a number of its peers in pharma with a plan to spin off its consumer health business into a separate company and focus its efforts on its prescription drugs ...
Benzinga.com3d
Sanofi Sells Global Rights To Rare Autoimmune Drug Enjaymo For $825M Upfront To Italian Firm Recordati
Also Read: FDA Approves Regeneron/Sanofi’s Blockbuster Dupixent For Smoker’s Lung Disease. The FDA approved the drug in 2022. Administered as chronic IV treatment. Enjaymo generated ...
Business Insider14d
Sanofi (SNYNF) Receives a Buy from Barclays
Barclays analyst Emily Field maintained a Buy rating on Sanofi (SNYNF – Research Report) today and set a price target of €120.00. The company’s shares closed last Friday at $115.80.
Sanofi, GSK, CSL tapped to expand US bird flu vaccine supply
The companies will use the funds to fill vials and pre-filled syringes with stockpiled vaccine ingredients, aimed at raising ...
Business Insider5d
Sanofi (SNYNF) Gets a Hold from J.P. Morgan
J.P. Morgan analyst Richard Vosser maintained a Hold rating on Sanofi (SNYNF – Research Report) today and set a price target of €100.00. The company’s shares closed last Tuesday at $114.50.
Reuters10d
Sanofi-Regeneron's Dupixent wins FDA's nod for 'smoker's lung'
Sept 27 (Reuters) - The U.S. Food and Drug Administration has approved Sanofi (SASY.PA), opens new tab and Regeneron's (REGN.O), opens new tab blockbuster drug Dupixent for patients with a chronic ...
MedCity News9d
Sanofi and Regeneron Biologic Drug Dupixent Notches a New FDA Approval in COPD
The blockbuster Sanofi and Regeneron Pharmaceuticals drug Dupixent, already commercialized in several skin and lung disorders, has expanded its FDA-approval to chronic obstructive pulmonary ...
STAT27d
After FDA rejection, Sanofi and Regeneron’s Dupixent succeeds in late-stage trial of chronic hives
Sanofi and Regeneron’s blockbuster drug Dupixent successfully treated patients with chronic spontaneous urticaria, an inflammatory skin disease, in a late-stage trial, the companies announced on ...
Recordati buys rights to rare immune disorder drug from Sanofi for $825 mln
Italian pharma group Recordati said on Friday it would buy from Sanofi the global rights to a drug used to treat cold ...
AOL3d
Recordati buys rights to rare immune disorder drug from Sanofi for $825 million
(Reuters) -Italian pharma group Recordati said on Friday it would buy from Sanofi the global rights to a drug used to treat cold agglutinin disease (CAD), a rare autoimmune disorder, for $825 ...